Antibiotic Selection for Diabetic Patients with Skin and Soft Tissue Infections

Introduction to Antibiotic Selection

The Infectious Diseases Society of America recommends clindamycin as the most appropriate choice for diabetic patients with skin and soft tissue infections, as it covers Staphylococcus aureus and Streptococcus species, the most likely pathogens 1

The American College of Clinical Pharmacy suggests classifying infection severity based on the extent of cellulitis, presence of systemic symptoms, and depth of tissue involvement, with mild infection being local inflammation extending <2 cm around the wound, moderate infection being cellulitis >2 cm or involving deeper structures, and severe infection being systemic signs or extensive tissue involvement 1, 2
A bulla on the thigh in a diabetic patient suggests at minimum a moderate skin and soft tissue infection, potentially representing bullous cellulitis or early necrotizing infection 4

The Infectious Diseases Society of America recommends starting clindamycin immediately, obtaining deep tissue cultures, assessing for surgical needs urgently, considering adding gram-negative coverage, and adding MRSA-specific therapy if necessary 1, 2, 3
The treatment duration should be 1-2 weeks for uncomplicated skin infections, extending to 2-3 weeks if extensive or slow to resolve, with monitoring of clinical response every 2-5 days initially 2, 3

The American College of Surgeons advises against delaying surgical evaluation if there are signs of necrotizing infection, as antibiotics alone are insufficient without adequate debridement 2, 4
The Infectious Diseases Society of America recommends against using unnecessarily broad empiric coverage for what appears to be a straightforward skin infection without risk factors for resistant organisms 5, 2
The American Diabetes Association suggests ensuring adequate glycemic control, as hyperglycemia impairs both infection eradication and wound healing 3